ABBV Cash & equivalents
Cash & equivalents at AbbVie fell to $5.2B in fiscal 2025, the lowest in the 5 years reported, from $5.5B in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 1551152 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$5.2B
FY2024 $5.5B
HIGH$12.8B FY2023
LOW$5.2B FY2025
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $5.2B | $-295M |
| FY2024 | $5.5B | $-7.3B |
| FY2023 | $12.8B | +$3.6B |
| FY2022 | $9.2B | $-545M |
| FY2021 | $9.7B | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · ABBV company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.